HS
CRBP icon

HighVista Strategies’s Corbus Pharmaceuticals CRBP Stock Holding History

HighVista Strategies’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-118,027
Closed -$1.49M – 156
2025
Q3 		$1.49M Buy
118,027
+42,735
+57% +$406K 0.37% 83
2025
Q2 		$520K Hold
75,292
– – 0.19% 124
2025
Q1 		$400K Hold
75,292
– – 0.15% 132
2024
Q4 		$888K Hold
75,292
– – 0.33% 106
2024
Q3 		$1.55M Buy
75,292
+36,499
+94% +$1.87M 0.54% 76
2024
Q2 		$1.76M Buy
+38,793
New +$1.63M 0.64% 52
2020
Q2 		– Sell
-407
Closed -$64K – 102
2020
Q1 		$64K Hold
407
– – 0.06% 35
2019
Q4 		$67K Hold
407
– – 0.05% 109
2019
Q3 		$59K Buy
+407
New +$70.9K 0.04% 108

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

HighVista Strategies's CRBP Position: Q4 2025 in Review

HighVista Strategies sold out of Corbus Pharmaceuticals (CRBP) in Q4 2025, closing a stake of 118,027 shares — an estimated $1.49M sold.

HighVista Strategies first reported a position in CRBP in Q3 2019 and held it in 9 quarters. The position peaked at $1.76M in Q2 2024. 100 funds tracked by Wall St. Rank hold CRBP as of Q4 2025.

  • HighVista Strategies reported no remaining Corbus Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • HighVista Strategies sold 118,027 Corbus Pharmaceuticals shares in Q4 2025, an estimated $1.49M.
  • HighVista Strategies first reported a position in Corbus Pharmaceuticals in Q3 2019 and held it in 9 quarters.
  • HighVista Strategies's Corbus Pharmaceuticals position peaked at $1.76M in Q2 2024.
  • 100 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2025.

Based on HighVista Strategies's 13F filing for Q4 2025, filed 17 Feb 2026.